My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
Resolution 2024-069
>
Meetings
>
2024
>
04. April
>
2024-04-16 10:00 AM - Commissioners' Agenda
>
Resolution 2024-069
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
5/22/2024 9:25:50 AM
Creation date
5/22/2024 9:24:53 AM
Metadata
Fields
Template:
Meeting
Date
4/16/2024
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Fully Executed Version
Supplemental fields
Item
Request to Approve a Resolution Accepting the Johnson & Johnson (Janssen) Washington State State-Wide Opioid Settlement Agreement
Order
7
Placement
Consent Agenda
Row ID
116716
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
130
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
overprescribing, opioid misuse, or opioid overdoses, treating those with OUD and any <br />co-occurring SUD/\4H conditions, supporting them in treatment or recovery, <br />connecting them to care, or implementing other strategies to abate the opioid <br />epidemic described in this opioid abatement strategy list. <br />4. Provide resources to staff govemment oversight and management of opioid abatement <br />programs. <br />K. TRAINING <br />In addition to the training refened to throughout this document, support training to abate <br />the opioid epidemic through activities, programs, or strategies that may include, but are <br />not limited to, those that: <br />l. Provide funding for staff training or networking programs and services to improve the <br />capability of government, community, and not-for-profit entities to abate the opioid <br />crisis. <br />2. Support infrastructure and staffing for collaborative cross-system coordination to <br />prevent opioid misuse, prevent overdoses, and treat those with OUD and any co- <br />occurring SUDA4H conditions, or implement other strategies to abate the opioid <br />epidemic described in this opioid abatement strategy list (e.g., health care, primary <br />care, pharmacies, PDMPs, etc.). <br />L. RESEARCH <br />Support opioid abatement research that may include, but is not limited to, the following: <br />1. Monitoring, surveillance, data collection and evaluation of programs and strategies <br />described in this opioid abatement strategy list. <br />2. Research non-opioid treatment of chronic pain. <br />3. Research on improved service delivery for modalities such as SBIRT that <br />demonstrate promising but mixed results in populations wlnerable to opioid use <br />disorders. <br />4. Research on novel harm reduction and prevention efforts such as the provision of <br />fentanyl test strips. <br />5. Research on innovative supply-side enforcement efforts such as improved detection <br />of mail-based delivery of synthetic opioids. <br />6. Expanded research on swift/certainlfafu models to reduce and deter opioid misuse <br />within criminaljustice populations that build upon promising approaches used to <br />address other substances (e.g., Hawaii HOPE and Dakota 2417). <br />I-14
The URL can be used to link to this page
Your browser does not support the video tag.